151 related articles for article (PubMed ID: 11757964)
1. Editorial commentary to Narayanan et al. Axonal metabolic recovery in multiple sclerosis patients treated with interferon beta-1b.
Matthews PM
J Neurol; 2001 Nov; 248(11):987. PubMed ID: 11757964
[No Abstract] [Full Text] [Related]
2. Axonal metabolic recovery in multiple sclerosis patients treated with interferon beta-1b.
Narayanan S; De Stefano N; Francis GS; Arnaoutelis R; Caramanos Z; Collins DL; Pelletier D; Arnason BGW ; Antel JP; Arnold DL
J Neurol; 2001 Nov; 248(11):979-86. PubMed ID: 11757963
[TBL] [Abstract][Full Text] [Related]
3. Multiple sclerosis and interferon beta-1b, past, present and future.
Horowski R
Clin Neurol Neurosurg; 2002 Jul; 104(3):259-64. PubMed ID: 12127665
[No Abstract] [Full Text] [Related]
4. Enhanced spasticity in primary progressive MS patients treated with interferon beta-1b.
Frese A; Bethke F; Lüdemann P; Stögbauer F
Neurology; 1999 Nov; 53(8):1892-3. PubMed ID: 10563657
[No Abstract] [Full Text] [Related]
5. Long-term benefits of early and high doses of interferon beta-1a treatment in relapsing-remitting multiple sclerosis.
Chofflon M; Ben-Amor AF
Clin Neurol Neurosurg; 2002 Jul; 104(3):244-8. PubMed ID: 12127662
[No Abstract] [Full Text] [Related]
6. The significance of neutralizing antibodies in patients with multiple sclerosis treated with interferon beta.
Rice G
Arch Neurol; 2001 Aug; 58(8):1297-8. PubMed ID: 11493173
[No Abstract] [Full Text] [Related]
7. [Interferon therapy of multiple sclerosis. A question of the correct dose?].
Hohlfeld R
Nervenarzt; 2001 Feb; 72(2):67-8. PubMed ID: 11256156
[No Abstract] [Full Text] [Related]
8. Rebif offers another option for treating multiple sclerosis.
Ryan M
J Am Pharm Assoc (Wash); 2002; 42(6):889-91. PubMed ID: 12482017
[No Abstract] [Full Text] [Related]
9. Treat early, but treat hard: Interferon-beta dose makes a difference.
Mikol DD
J Neuroophthalmol; 2001 Dec; 21(4):237-9. PubMed ID: 11756850
[No Abstract] [Full Text] [Related]
10. The effect of interferon beta-1a on spasticity in primary progressive multiple sclerosis.
Leary SM; Thompson AJ
J Neurol Neurosurg Psychiatry; 2004 Mar; 75(3):508-9. PubMed ID: 14966181
[No Abstract] [Full Text] [Related]
11. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN).
Durelli L; Verdun E; Barbero P; Bergui M; Versino E; Ghezzi A; Montanari E; Zaffaroni M;
Lancet; 2002 Apr; 359(9316):1453-60. PubMed ID: 11988242
[TBL] [Abstract][Full Text] [Related]
12. Treatment of multiple sclerosis with interferon beta 1b.
Dhib-Jalbut S; McFarland HF
Baillieres Clin Neurol; 1997 Oct; 6(3):467-80. PubMed ID: 10101584
[TBL] [Abstract][Full Text] [Related]
13. Multiple sclerosis: what have we learned from magnetic resonance imaging studies?
Khoury SJ; Weiner HL
Arch Intern Med; 1998 Mar; 158(6):565-73. PubMed ID: 9521220
[TBL] [Abstract][Full Text] [Related]
14. Comparative effects of interferon-consensus 1, interferon-alpha 2a, and interferon-beta 1b on HLA expression and lymphoproliferation: a preclinical model for treatment of multiple sclerosis.
Dhib-Jalbut S; Jiang H; Xia Q; Blatt L; Johnson KP; Hilt D
J Interferon Cytokine Res; 1996 Mar; 16(3):195-200. PubMed ID: 8697141
[TBL] [Abstract][Full Text] [Related]
15. To treat, or not to treat: the therapeutic dilemma of idiopathic monosymptomatic demyelinating syndromes.
Frohman EM; Racke M; van Den Noort S
Arch Neurol; 2000 Jul; 57(7):930-2. PubMed ID: 10891973
[No Abstract] [Full Text] [Related]
16. Experiences with interferon-beta-1b treatment in MS after three year follow-up.
Bencsik K; Rajda C; Füvesi J; Járdánházy T; Török M; Vécsei L
Swiss Med Wkly; 2002 May; 132(17-18):237. PubMed ID: 12087490
[No Abstract] [Full Text] [Related]
17. [Clinical efficacy and safety of long-term immunomodulating therapy with interferon beta].
Demina TL; Khachanova NV; Davydovskaia MV; Popova NF; Gusev EI
Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(4):24-6. PubMed ID: 18567192
[No Abstract] [Full Text] [Related]
18. New onset of rheumatoid arthritis during interferon beta-1B treatment in a patient with multiple sclerosis: comment on the case report by Jabaily and Thompson.
Alsalameh S; Manger B; Kern P; Kalden J
Arthritis Rheum; 1998 Apr; 41(4):754. PubMed ID: 9550494
[No Abstract] [Full Text] [Related]
19. Key issues in the diagnosis and treatment of multiple sclerosis. An overview.
O'Connor P;
Neurology; 2002 Sep; 59(6 Suppl 3):S1-33. PubMed ID: 12448786
[No Abstract] [Full Text] [Related]
20. Neutralizing antibodies and the efficacy of interferon beta-1b in relapsing-remitting multiple sclerosis.
Petkau J; White R
Mult Scler; 1997 Dec; 3(6):402. PubMed ID: 9493643
[No Abstract] [Full Text] [Related]
[Next] [New Search]
